According to the offshore protein announcement, the daily closing price increase deviation value of the company's stock exceeded 30% for 3 consecutive trading days on October 28, October 29, and October 30, 2026, which is an abnormal fluctuation in stock trading. After self-inspection and consultation with the controlling shareholders and actual controllers, there was no significant information that should be disclosed but not disclosed. The directors, supervisors, controlling shareholders, and actual controllers did not trade the company's shares during the change period. The company's net loss to mother for the first three quarters of 2026 was 479.034 million yuan, an increase of 19.041 million yuan over the same period last year. As of the close of trading on October 30, 2026, the company's market sales ratio was 66.18, which is significantly higher than that of comparable companies in the same industry; high-throughput wet experiments and data package services that enable AI are still in the early stages of market expansion. Related businesses accounted for less than 2% of revenue in the first three quarters. There is uncertainty about commercial implementation, reminding investors to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.